Various pathological processes can lead to liver fibrosis and cirrhosis e.g., viral or bacterial infections, alcoholic liver disease (ALD), nonalcoholic steatohepatitis (NASH), metabolic associated fatty liver disease (MAFLD), or autoimmune hepatitis (AIH). The nonobese diabetic inflammation and fibrosis (NIF) mouse model allows researchers to study key pathological processes of these indications and is a pivotal tool to more effectively validating new drugs against liver inflammation and fibrosis.
‘’Our motto ‘a smart road to better health’ signifies the aim to provide our customers with high-quality research models that support drug development in disease areas that have an enormous unmet medical need. As such, the NIF mouse model provides a valuable addition to the InnoSer portfolio of cardio-metabolic services. InnoSer hopes to increase the accessibility of this valuable NIF model and further strengthen its proposition by combining it with InnoSer’s drug development platform capabilities including histopathology and bioanalytical services”
– Jan Bartels, InnoSer CEO.
In the NIF model, a transgenic NKT cell population induces spontaneous early onset liver fibrosis, preceded by chronic inflammation. The inflammatory/fibrotic phenotype of the NIF mouse shows large similarities with human NASH/MAFLD, including hepatic stellate cell and NLRP3 inflammasome activation. The combination of early onset inflammation and fibrosis and 100% phenotype reproducibility makes the NIF mouse an excellent model for efficacy testing of drugs that target these events. Because of the model’s unique development of inflammation/fibrosis that is not preceded by metabolic stress, the NIF mouse allows researchers to separate potential immunological effects from metabolic effects. InnoSer’s additional services, such as histopathology services, provide researchers with additional tools to gain deep insight into key molecular steps in liver inflammation and fibrosis in relation to their compound’s mode of action.
” The collaboration with InnoSer is a great opportunity both for InfiCure as a company, but also for clients all over the world since it will increase the possibilities to use our NIF mouse for efficacy testing.”
– Sofia Mayans, InfiCure Bio CEO.
For further information, please contact:
Sofia Mayans, PhD, CEO, Inficure Bio
+46 70-366 46 66
About Inficure Bio
InfiCure Bio is a contract research organization located in Sweden focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions. The company was founded in 2015 by Prof. Dan Holmberg and Dr. Sofia Mayans based on the extensive experience and expertise in immunology, inflammation, and fibrosis of its founders. InfiCure offers drug development services based on a panel of in vivo models for these indications including the proprietary NIF mouse model. The latter serves as a game-changing tool for pharma developers to validate new drugs more effectively against liver fibrosis.
Read more about InfiCure Bio here.
Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting preclinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug development journey with well characterized in vitro and in vivo disease models in addition to general drug development services, allowing to uncover valuable insights into the mode of action, pharmacokinetics, safety, and efficacy of investigational compounds. InnoSer’s offerings include a unique ADPKD mouse model for nephrology, golden standard immunology and oncology and a proprietary PDX/O screening platform, neurodegenerative and neuromuscular disease models and, most recently, a selection of well characterized cardio-metabolic disease models. InnoSer also provides toxicology and pharmacokinetics studies, in vivo imaging, pathology, and we offer facility management solutions together with rodent colony management services.
Read more about InnoSer here.